$SAGE reversal trade opportunity
Yesterdays selloff may present a good opportunity to get a reversal trade, the poor trial results are quite a Mich mash but what was ignored was the fact that some of the group had actually not taken the drug dosage required. I am not medical expert so only look at this on a technical level and see a chance for a dead cat bounce at the minimum.
The RSI is at all time low so will automatically attract some day traders today.
Found support and bounced amid the carnage yesterday.
short interest 10.80% may start a short covering rally.
Company profile
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
The RSI is at all time low so will automatically attract some day traders today.
Found support and bounced amid the carnage yesterday.
short interest 10.80% may start a short covering rally.
Company profile
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.